CDK4 and cancer: Clinical inhibitors of CDK4/6 kinases have been approved as a therapeutic for estrogen receptor-positive breast cancers, and more than 100 clinical trials are currently evaluating CDK4/6 inhibitors in cancer treatment2–5.